Combination of uroguanylin and cyclooxygenase-2 inhibitors for intestinal cancer inhibition

摘要

Disclosed is a method of retarding the development of polyps and prevention, inhibition and treatment of cancer in the intestine of a subject by administration of a composition comprising a peptide with the active domain of uroguanylin or any agonist peptide or compound binding to the guanylate cyclase receptor GC-C in the intestine in combination with a naturally occurring, derived from a naturally occurring, or a chemically synthesized cycloogenase-2 inhibitor, preferably a selective cyclooxygenase-2 inhibitor.